Salute e Benessere
Medical Aesthetics Market to Hit US$ 35.32 Billion by 2030 with 12.8% CAGR | MarketsandMarkets™.
the medical aesthetics market is categorized into facial aesthetic products, cosmetics implants, skin aesthetic devices, body contouring devices, physician-dispensed cosmeceuticals and skin lighteners, hair removal devices, tattoo removal devices, thread lift products, Physician- dispensed eyelash products and nail treatment laser devices. For the year 2023, facial aesthetics products consisting of botulinum toxins, dermal fillers, and chemical peels held the largest of the medical aesthetics market.
The medical aesthetics market is segmented into standalone devices, multimodal devices, and at-home or self-use devices. For medical aesthetics procedures, standalone devices are preferred more by surgeons due to their interactive and smooth interface. Such characteristics make standalone devices more viable for end users like hospitals, and beauty clinics.
in terms of procedure the medical aesthetics market is divided into two main categories: surgical and non-surgical procedures. Surgical procedures include options such as breast augmentation, rhinoplasty, facelifts, body lifts, and other similar interventions. On the other hand, non-surgical procedures encompass treatments like anti-aging and skin rejuvenation, tattoo and scar removal, hair removal, lipolysis, and various other non-surgical options. Non-surgical procedures are generally preferred by consumers due to their shorter recovery times and lower risk of complications, such as infections. These advantages have contributed to non-surgical procedures capturing the largest share of the medical aesthetics market in terms of the number of procedures performed.
the medical aesthetics market is categorized into clinics, hospitals, medical spas, beauty centers, and home care settings. Growth in this segment can attributed to advancements in technologies specifically in clinics, hospitals, and medical spa settings helping them to acquire more consumers. The same thing has helped hospitals, clinics, and medical spas to acquire the largest share of medical aesthetics market in terms of end users. At the same time, it's anticipated that the coming time will observe an increase in the elderly population. Such conditions will create a need for solutions aiming at maintaining health and physical appearance which will help to grow the market for medical aesthetics.
North America accounts for the highest share of the medical aesthetics market. This is due to strategic initiatives by the market players in the region, a growing number of concerns regarding aesthetics treatment, and the aesthetics healthcare infrastructure. The US has a higher adoption rate of innovative technologies as compared to other countries, which is a major factor responsible for the large share of the US in the North American medical aesthetics market. Availability of advanced and user-friendly products are the other major factors responsible for the growth of the market.
The market of medical aesthetics is moderately competitive, where there exist established companies and upcoming competitors for the same market share. As of 2022, key players that operate in the global medical aesthetic market are Abbvie Inc (US), Galderma ( Switzerland ), Johnson & Johnson (US), Bausch Health Companies Inc. ( Canada ), and Cutera. (US) among others.
These competitors have employed several strategies to gain an advantage in the global medical aesthetics market through mergers and acquisitions, agreements, partnerships, and new product launches. In 2022, Abbvie Inc. (US), Bausch Health Companies Inc. ( Canada ), and Johnson & Johnson (US) possessed a larger share in the medical aesthetics market.
AbbVie is a global biopharmaceutical company with six product segments: Immunology, Hematologic Oncology, Aesthetics, Neuroscience, Eye Care, and Other Key Products. Their Aesthetics division provides a wide range of solutions, such as Botox Cosmetic, Juvederm Collection, and other aesthetic products, including facial injectables, regenerative medicine, body contouring, and skincare items.
Abbvie is among the leading companies in the global medical aesthetics market. A strong focus on research and innovation to discover and develop innovative pharmaceutical products with a diversified global presence are the company's major strengths and help in keeping its product pipeline robust.
AbbVie has strategically positioned itself as one of the most well-known biopharmaceutical companies globally, especially in the Aesthetics market. The company continues to expand its portfolio with FDA approvals and launches of new product lines, such as Botox Cosmetic for facial treatments, the Juvéderm Collection for restoring lost volume, and SKINVIVE to smoothen cheek skin. All these products are gaining more aesthetic demand and place AbbVie at a better competitive advantage in the skincare marketplace. Others, AbbVie just innovated further in body contouring with CoolSculpting and diversified its medical solutions in Neuroscience, Oncology, and Eye Care.
The company's core strength, however, remains its innovative portfolio of products and strong regulatory achievements, making the company a leader in dermatology and injectable aesthetics. Indeed, successful FDA approvals for cutting-edge treatments such as Restylane Eye light, Restylane Contour, and Restylane Define highlight Galderma's superiority in considering almost any aesthetic demand-from hollowing under the eyes to chin augmentation. Further proof of commitment towards technological advancements, Galderma launched "FACE by Galderma" - an augmented reality device that has augmented treatment planning. With good manufacturing capabilities, a new facility in Singapore and a direction towards digitalization and automation, Galderma is prepared for sustainable growth.
Galderma maintains its strategic focus on innovation and global growth with strategic alliances in reinforcement of dermatology dominance. The company distinguishes itself with advanced technologies, one of which is the PLLA-SCA technology of Sculptra, a collagen stimulator that targets signs of aging. A wide variety of products in injectable aesthetics, dermo- cosmetic, and therapeutic dermatology underline effective solutions against various skin issues and are on offer by Galderma.
Johnson & Johnson's competitive advantages in the medical aesthetics market are based on its wide-range product portfolio, international presence, and mastery of advanced healthcare technologies. One of its products in the Mentor line of breast implants, particularly MemoryGel, MemoryShape, and SILTEX, is reflective of innovation regarding features that can offer natural aesthetics, flexibility in options, and advanced materials for augmentation and reconstruction. The group's presence in all major regions and the subsidiary support of Janssen Pharmaceuticals, Neutrogena, and Ethicon Inc. help to penetrate every critical market around the globe. Furthermore, as a leader in healthcare and the capability to cater to a variety of provider and patient needs, the company strongly reiterates its leadership in the industry for medical aesthetics.
Johnson & Johnson has undertaken strategic efforts that enhance its position in the medical aesthetics market. Such strategic moves included the acquisition of Mentor Worldwide LLC in 2009, which expanded its portfolio in surgical aesthetics as well as breast implant technologies. As an independent business under Ethicon, J&J ensured that it remained in a better position concerning leadership in breast aesthetics while responding to the growing demand for cosmetic and reconstructive procedures. Also, the company has emphasized innovation, providing sophisticated implants that ultimately improve the patient's outcome. Its investment in a sound global distribution network and strategic collaboration with providers of healthcare services prove that it is working effectively to ensure product availability and maintain a competitive edge.
For more information,
Get access to the latest updates on and
MarketsandMarkets™ has been recognized as one of , as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit
www.MarketsandMarkets™.com or follow us on
Twitter ,
LinkedIn and
Facebook .
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
View original content: https://www.prnewswire.co.uk/news-releases/medical-aesthetics-market-to-hit-us-35-32-billion-by-2030-with-12-8-cagr--marketsandmarkets-302336922.html